Amedisys, Inc. (AMED) Forms $51.42 Double Bottom; 2 Analysts Bullish Alliqua BioMedical, Inc. (ALQA)

Amedisys, Inc. (AMED) formed double bottom with $47.82 target or 7.00% below today’s $51.42 share price. Amedisys, Inc. (AMED) has $1.75 billion valuation. The stock decreased 1.80% or $0.94 during the last trading session, reaching $51.42. About 268,957 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 15.02% since February 4, 2017 and is uptrending. It has underperformed by 1.68% the S&P500.

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Hold” rating by Zacks given on Wednesday, August 19. As per Friday, April 7, the company rating was maintained by H.C. Wainwright. RBC Capital Markets maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) rating on Wednesday, February 24. RBC Capital Markets has “Outperform” rating and $3 target. As per Monday, January 8, the company rating was downgraded by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $2.50 target in Wednesday, August 10 report. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, January 3 report. The firm has “Outperform” rating given on Friday, November 6 by RBC Capital Markets. On Friday, November 6 the stock rating was maintained by Chardan Capital Markets with “Buy”. As per Wednesday, February 24, the company rating was maintained by Chardan Capital Markets. H.C. Wainwright maintained Alliqua BioMedical, Inc. (NASDAQ:ALQA) rating on Monday, November 2. H.C. Wainwright has “Buy” rating and $10.0 target. See Alliqua BioMedical, Inc. (NASDAQ:ALQA) latest ratings:

08/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $1.5 Downgrade
03/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain
11/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $1.5000

Investors sentiment decreased to 1.71 in 2017 Q3. Its down 0.04, from 1.75 in 2017Q2. It dived, as 26 investors sold Amedisys, Inc. shares while 29 reduced holdings. 30 funds opened positions while 64 raised stakes. 31.75 million shares or 5.19% more from 30.18 million shares in 2017Q2 were reported. New York-based Etrade Cap Mngmt Ltd Liability has invested 0.01% in Amedisys, Inc. (NASDAQ:AMED). State Board Of Administration Of Florida Retirement Systems has 19,658 shares. Virginia Retirement System Et Al reported 0.02% stake. Deutsche Fincl Bank Ag accumulated 28,985 shares. Wells Fargo And Mn reported 1.48 million shares. Citigroup accumulated 20,152 shares. State Street has invested 0% in Amedisys, Inc. (NASDAQ:AMED). Moreover, Riggs Asset Managment Co has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED) for 450 shares. Geode Cap Management Ltd Liability Co has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED) for 286,772 shares. New York State Teachers Retirement Systems holds 0.01% or 78,511 shares in its portfolio. Bank & Trust Of America Corporation De accumulated 73,602 shares or 0% of the stock. Northern Trust Corp holds 0.01% or 797,851 shares in its portfolio. Parametric Portfolio Associates Limited Liability Corp stated it has 83,106 shares. Ameriprise Fincl owns 177,536 shares or 0% of their US portfolio. Amer Grp Inc Inc holds 0% or 22,560 shares in its portfolio.

Analysts await Amedisys, Inc. (NASDAQ:AMED) to report earnings on February, 27. They expect $0.59 EPS, up 34.09% or $0.15 from last year’s $0.44 per share. AMED’s profit will be $20.02 million for 21.79 P/E if the $0.59 EPS becomes a reality. After $0.56 actual EPS reported by Amedisys, Inc. for the previous quarter, Wall Street now forecasts 5.36% EPS growth.

Among 15 analysts covering Amedisys Inc. (NASDAQ:AMED), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Amedisys Inc. has $68.0 highest and $39 lowest target. $58.73’s average target is 14.22% above currents $51.42 stock price. Amedisys Inc. had 37 analyst reports since September 1, 2015 according to SRatingsIntel. RBC Capital Markets maintained Amedisys, Inc. (NASDAQ:AMED) on Friday, May 6 with “Sector Perform” rating. Mizuho maintained the shares of AMED in report on Wednesday, November 8 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, July 19 report. RBC Capital Markets maintained the shares of AMED in report on Monday, June 5 with “Hold” rating. The firm has “Hold” rating by RBC Capital Markets given on Monday, August 14. The firm has “Hold” rating given on Monday, July 10 by RBC Capital Markets. The rating was maintained by Robert W. Baird with “Neutral” on Wednesday, January 13. The stock of Amedisys, Inc. (NASDAQ:AMED) has “Hold” rating given on Sunday, October 22 by RBC Capital Markets. The firm has “Neutral” rating by Mizuho given on Wednesday, July 26. Mizuho upgraded the stock to “Buy” rating in Tuesday, January 19 report.

The stock decreased 2.38% or $0.05 during the last trading session, reaching $2.05. About 39,175 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 66.38% since February 4, 2017 and is downtrending. It has underperformed by 83.08% the S&P500.